- Home
- GIFT vs BLRX Comparison
GIFT vs BLRX Comparison
Compare GIFT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIFT | BLRX |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 12.6M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GIFT | BLRX |
|---|---|---|
| Price | $1.10 | $3.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 64.8K | 21.5K |
| Earning Date | 11-10-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $86,142,442.00 | $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $2.30 |
| 52 Week High | $2.38 | $7.77 |
Technical Indicators
Market Signals| Indicator | GIFT | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 56.99 |
| Support Level | $1.06 | $2.82 |
| Resistance Level | $1.14 | $3.08 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 58.25 | 99.07 |
Price Performance
Historical ComparisonAbout GIFT RDE Inc.
Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.